These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 34743725)

  • 1. Polygenic risk score across distinct colorectal cancer screening outcomes: from premalignant polyps to colorectal cancer.
    Obón-Santacana M; Díez-Villanueva A; Alonso MH; Ibáñez-Sanz G; Guinó E; López A; Rodríguez-Alonso L; Mata A; García-Rodríguez A; Palomo AG; Molina AJ; Garcia M; Binefa G; Martín V; Moreno V
    BMC Med; 2021 Nov; 19(1):261. PubMed ID: 34743725
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combined Performance of Fecal Immunochemical Tests and a Genetic Risk Score for Advanced Neoplasia Detection.
    Niedermaier T; Guo F; Weigl K; Hoffmeister M; Brenner H
    Cancer Prev Res (Phila); 2022 Aug; 15(8):543-552. PubMed ID: 35679356
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluating the Potential of Polygenic Risk Score to Improve Colorectal Cancer Screening.
    Arnau-Collell C; Díez-Villanueva A; Bellosillo B; Augé JM; Muñoz J; Guinó E; Moreira L; Serradesanferm A; Pozo À; Torà-Rocamora I; Bonjoch L; Ibañez-Sanz G; Obon-Santacana M; Moratalla-Navarro F; Sanz-Pamplona R; Márquez Márquez C; Rueda Miret R; Pérez Berbegal R; Piquer Velasco G; Hernández Rodríguez C; Grau J; Castells A; Borràs JM; Bessa X; Moreno V; Castellví-Bel S
    Cancer Epidemiol Biomarkers Prev; 2022 Jul; 31(7):1305-1312. PubMed ID: 35511747
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fecal MicroRNA-Based Algorithm Increases Effectiveness of Fecal Immunochemical Test-Based Screening for Colorectal Cancer.
    Duran-Sanchon S; Moreno L; Gómez-Matas J; Augé JM; Serra-Burriel M; Cuatrecasas M; Moreira L; Serradesanferm A; Pozo À; Grau J; Pellisé M; Gironella M; Castells A
    Clin Gastroenterol Hepatol; 2021 Feb; 19(2):323-330.e1. PubMed ID: 32113893
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interval Colorectal Cancer Incidence Among Subjects Undergoing Multiple Rounds of Fecal Immunochemical Testing.
    van der Vlugt M; Grobbee EJ; Bossuyt PMM; Bos A; Bongers E; Spijker W; Kuipers EJ; Lansdorp-Vogelaar I; Spaander MCW; Dekker E
    Gastroenterology; 2017 Aug; 153(2):439-447.e2. PubMed ID: 28483499
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fecal Immunochemical Testing in Patients With Low-Risk Symptoms of Colorectal Cancer: A Diagnostic Accuracy Study.
    Ball AJ; Aziz I; Parker S; Sargur RB; Aldis J; Kurien M
    J Natl Compr Canc Netw; 2022 Sep; 20(9):989-996.e1. PubMed ID: 36075395
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of Polygenic Risk Scores to Select Screening Intervals After Negative Findings From Colonoscopy.
    Guo F; Weigl K; Carr PR; Heisser T; Jansen L; Knebel P; Chang-Claude J; Hoffmeister M; Brenner H
    Clin Gastroenterol Hepatol; 2020 Nov; 18(12):2742-2751.e7. PubMed ID: 32376506
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genome-wide polygenic risk scores for colorectal cancer have implications for risk-based screening.
    Tamlander M; Jermy B; Seppälä TT; Färkkilä M; ; Widén E; Ripatti S; Mars N
    Br J Cancer; 2024 Mar; 130(4):651-659. PubMed ID: 38172535
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fecal occult blood test for colorectal cancer screening: an evidence-based analysis.
    Medical Advisory Secretariat
    Ont Health Technol Assess Ser; 2009; 9(10):1-40. PubMed ID: 23074514
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Variation of Positive Predictive Values of Fecal Immunochemical Tests by Polygenic Risk Score in a Large Screening Cohort.
    Niedermaier T; Balavarca Y; Gies A; Weigl K; Guo F; Alwers E; Hoffmeister M; Brenner H
    Clin Transl Gastroenterol; 2022 Jan; 13(3):e00458. PubMed ID: 35060941
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Research on applying genetic and environmental risk score in risk-adapted colorectal cancer screening].
    Luo CY; Zhang YH; Lu M; Lu B; Cai J; Li N; Zhou YY; Luo JH; Zhang DD; Yang XZ; Chen HD; Dai M
    Zhonghua Liu Xing Bing Xue Za Zhi; 2023 Jun; 44(6):999-1005. PubMed ID: 37380425
    [No Abstract]   [Full Text] [Related]  

  • 12. Results of National Colorectal Cancer Screening Program in Croatia (2007-2011).
    Katičić M; Antoljak N; Kujundžić M; Stamenić V; Skoko Poljak D; Kramarić D; Stimac D; Strnad Pešikan M; Samija M; Ebling Z
    World J Gastroenterol; 2012 Aug; 18(32):4300-7. PubMed ID: 22969192
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Polygenic Risk Score for Defining Personalized Surveillance Intervals After Adenoma Detection and Removal at Colonoscopy.
    Guo F; Edelmann D; Cardoso R; Chen X; Carr PR; Chang-Claude J; Hoffmeister M; Brenner H
    Clin Gastroenterol Hepatol; 2023 Jan; 21(1):210-219.e11. PubMed ID: 35331942
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of a New-generation Fecal Immunochemical Test (FIT) With Guaiac Fecal Occult Blood Test (gFOBT) in Detecting Colorectal Neoplasia Among Colonoscopy-referral Patients.
    Guimarães DP; Fregnani JH; Reis RM; Taveira LN; Scapulatempo-Neto C; Matsushita M; Silva SRM; Oliveira CZ; Longatto-Filho A; Eklund C; Paloheimo L; Mauad E; Suovaniemi O; Syrjänen K
    Anticancer Res; 2019 Jan; 39(1):261-269. PubMed ID: 30591467
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Participant-Related Risk Factors for False-Positive and False-Negative Fecal Immunochemical Tests in Colorectal Cancer Screening: Systematic Review and Meta-Analysis.
    de Klerk CM; Vendrig LM; Bossuyt PM; Dekker E
    Am J Gastroenterol; 2018 Dec; 113(12):1778-1787. PubMed ID: 30158713
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lower risk of advanced neoplasia among patients with a previous negative result from a fecal test for colorectal cancer.
    Denters MJ; Deutekom M; Bossuyt PM; Stroobants AK; Fockens P; Dekker E
    Gastroenterology; 2012 Mar; 142(3):497-504. PubMed ID: 22108194
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risk factors for colorectal cancer in a fecal immunochemical test-positive group: The National Health Insurance Service-National Health Screening Cohort.
    Park JH; Cho KH; Choi J; Chun S; Lee JK; Cho H; Kim B
    J Gastroenterol Hepatol; 2024 Jan; 39(1):74-80. PubMed ID: 37855299
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Colorectal Cancer screening in ambulatory healthcare service clinics in Abu Dhabi, United Arab Emirates in 2015-2016.
    Almansoori A; Alzaabi M; Alketbi L
    BMC Cancer; 2021 Aug; 21(1):897. PubMed ID: 34362343
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term performance of colorectal cancerscreening programmes based on the faecal immunochemical test.
    Zorzi M; Hassan C; Capodaglio G; Fedato C; Montaguti A; Turrin A; Rosano A; Monetti D; Stocco C; Baracco S; Russo F; Repici A; Rugge M
    Gut; 2018 Dec; 67(12):2124-2130. PubMed ID: 29101260
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Incidence of Interval Colorectal Cancer After Negative Results From First-Round Fecal Immunochemical Screening Tests, by Cutoff Value and Participant Sex and Age.
    Toes-Zoutendijk E; Kooyker AI; Dekker E; Spaander MCW; Opstal-van Winden AWJ; Ramakers C; Buskermolen M; van Vuuren AJ; Kuipers EJ; van Kemenade FJ; Velthuysen MF; Thomeer MGJ; van Veldhuizen H; van Ballegooijen M; Nagtegaal ID; de Koning HJ; van Leerdam ME; Lansdorp-Vogelaar I;
    Clin Gastroenterol Hepatol; 2020 Jun; 18(7):1493-1500. PubMed ID: 31442598
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.